Hyperlipidemia / ASCVD Prevention
Risk-stratify and treat lipids — statin intensity, LDL thresholds, add-on agents, and the role of CAC.
Learning Objectives
- 1.Risk-stratify patients into ASCVD treatment groups.
- 2.Select statin intensity and recognize when to add non-statin agents.
- 3.Use LDL thresholds, CAC, and monitoring appropriately.
Overview
Lipid management is high-yield prevention. The framework is: identify the risk group, start the right statin intensity, then add agents to reach LDL thresholds in higher-risk patients.
Why this matters
LDL lowering reduces ASCVD events proportionally to the reduction. The biggest gains come from getting high-risk patients on adequate therapy and keeping them on it.
The four statin-benefit groups
- •Clinical ASCVD (secondary prevention) → high-intensity statin.
- •LDL ≥190 mg/dL → high-intensity statin.
- •Diabetes, age 40–75 → at least moderate-intensity (high if higher risk).
- •Primary prevention (40–75, LDL 70–189) → estimate 10-year ASCVD risk and use shared decision-making.
Statin intensity & LDL thresholds
- •High-intensity statins lower LDL ~≥50%; moderate ~30–49%.
- •Very high-risk ASCVD: aim LDL <55 (≥50% reduction); add-on therapy if above threshold.
- •Primary-prevention threshold often LDL ≥70 to intensify in higher-risk patients.
Add-on (non-statin) agents
- •Ezetimibe — first add-on when not at goal on a maximally tolerated statin.
- •PCSK9 inhibitors — for high-risk patients still above threshold (or statin-intolerant).
- •Bempedoic acid — an option in statin intolerance.
- •Very high triglycerides → address (pancreatitis risk); icosapent ethyl in selected high-risk patients.
When CAC helps
- •Coronary artery calcium score helps refine risk in selected intermediate-risk primary-prevention patients when the statin decision is uncertain.
- •CAC of 0 supports deferring statin in selected patients; high CAC supports treating. Not used in acute chest pain.
Monitoring & safety
- •Recheck a lipid panel ~4–12 weeks after start/change to assess response/adherence.
- •Statin muscle symptoms: evaluate, consider dose/agent change — don’t reflexively stop forever.
- •Screen for secondary causes (hypothyroidism, etc.) when appropriate.
Red flags / escalation
- •Very high triglycerides (pancreatitis risk); suspected familial hypercholesterolemia (very high LDL, family history) for specialist input.
Common beginner mistakes
- •Under-dosing statins in secondary prevention.
- •Stopping a statin permanently for minor or non-statin muscle aches.
- •Forgetting to add ezetimibe/PCSK9 when above threshold.
- •Using CAC in the wrong setting (acute chest pain).
Tools
- •The Lipid Routing Tool turns values into risk category, LDL goal, and documentation (see Clinical Tools).
Nurse / MA workflow connection
- •Nurses route lipid results and adherence; MAs reconcile statin use and flag muscle complaints.
Mini cases
Post-MI patient on moderate-intensity statin; LDL returns 92.
Adjustment?
Show answer
Secondary prevention warrants high-intensity statin and an LDL goal <55. Intensify to high-intensity; if still above threshold, add ezetimibe, then consider a PCSK9 inhibitor. 92 is well above target for this very-high-risk patient.
Healthy 52-year-old, intermediate 10-year risk, ambivalent about a statin.
How can CAC help?
Show answer
A coronary calcium score can refine the decision: CAC 0 supports deferring, a meaningful score supports starting. It’s a good tie-breaker for intermediate-risk primary prevention.